Cargando…
The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
BACKGROUND: Fingolimod (FTY-720) has shown efficacy in relapsing multiple sclerosis (MS), while some side effects of this drug have been recognized that the most important is cardiovascular side effects. The aim of this study was to evaluate the cardiovascular side effects of FTY-720. However, the e...
Autores principales: | Abdar, Morteza, Ebrahimifar, Payam, Etemadifar, Masoud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455326/ https://www.ncbi.nlm.nih.gov/pubmed/28607567 |
Ejemplares similares
-
Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021) -
Cardiovascular effects of fingolimod: A review article
por: Behjati, Mohaddeseh, et al.
Publicado: (2014) -
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021) -
Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018) -
Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)